Drug name - Ozempic
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(3 years from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(9 years from now) | |
| CN101133082A | NOVO | Acylated Glp-1 Compound |
Mar, 2026
(3 years from now) | |
| CN101133082B | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| IN262697B | NOVO | Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue |
Mar, 2026
(3 years from now) | |
| IN200705107P1 | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| EP2322546B1 | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| EP2322546A1 | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| EP1863839B1 | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| EP1863839A2 | NOVO | Acylated Glp-1 Compounds |
Mar, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8579869 | NOVO | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(8 months from now) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 months from now) | |
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(2 years from now) | |
| US8684969 | NOVO | Injection device with torsion spring and rotatable display |
Oct, 2025
(3 years from now) | |
| US9108002 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
| US9861757 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(3 years from now) | |
| US9616180 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
| US10357616 | NOVO | Injection device with an end of dose feedback mechanism |
Jan, 2026
(3 years from now) | |
| US10376652 | NOVO | Automatic injection device with a top release mechanism |
Jan, 2026
(3 years from now) | |
| US8920383 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US10220155 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| US9775953 | NOVO | Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left |
Jul, 2026
(3 years from now) | |
| US11097063 | NOVO | Syringe device with a dose limiting mechanism and an additional safety mechanism |
Jul, 2026
(3 years from now) | |
| USRE46363 | NOVO | Dial-down mechanism for wind-up pen |
Aug, 2026
(3 years from now) | |
| US9687611 | NOVO | Injection device with torsion spring and rotatable display |
Feb, 2027
(4 years from now) | |
| US9457154 | NOVO | Injection device with an end of dose feedback mechanism |
Sep, 2027
(4 years from now) | |
| US9132239 | NOVO | Dial-down mechanism for wind-up pen |
Feb, 2032
(9 years from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(10 years from now) | |
Drugs and Companies using SEMAGLUTIDE ingredient
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof
Dosage: SOLUTION;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 2MG/1.5ML (1.34MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
| 4MG/3ML (1.34MG/ML) | SOLUTION;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.